CP
SPRY icon

CenterBook Partners’s ARS Pharmaceuticals SPRY Stock Holding History

CenterBook Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$990K Sell
123,624
-167,555
-58% -$1.44M 0.05% 355
2026
Q1 		$2.34M Sell
291,179
-277,182
-49% -$2.66M 0.13% 208
2025
Q4 		$6.62M Buy
568,361
+55,994
+11% +$545K 0.32% 78
2025
Q3 		$5.15M Buy
+512,367
New +$7.35M 0.25% 109

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

CenterBook Partners's SPRY Position: Q2 2026 in Review

CenterBook Partners reduced its ARS Pharmaceuticals (SPRY) stake by 58% in Q2 2026, selling an estimated $1.44M and leaving 123,624 shares worth $990K. The position accounts for 0.05% of the portfolio, ranked #355.

CenterBook Partners first reported a position in SPRY in Q3 2025 and has held it in 4 quarters since. The position peaked at $6.62M in Q4 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • CenterBook Partners held 123,624 shares of ARS Pharmaceuticals worth $990K as of Q2 2026.
  • CenterBook Partners sold 167,555 ARS Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
  • ARS Pharmaceuticals made up 0.05% of CenterBook Partners's portfolio in Q2 2026, its #355 holding.
  • CenterBook Partners first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • CenterBook Partners's ARS Pharmaceuticals position peaked at $6.62M in Q4 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.